Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy

Behaviour Research and Therapy

Volumn 51, Issue 7, 2013, Pages 392-398

  Fournier, Jay C ^a   DeRubeis, Robert J ^b   Hollon, Steven D ^c   Gallop, Robert ^d   Shelton, Richard C ^e   Amsterdam, Jay D ^f  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d WEST CHESTER UNIVERSITY   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ADM; Antidepressant medication; Cognitive therapy; CT; Paroxetine; PBO; Symptom reduction; Treatment for depression

Indexed keywords

DESIPRAMINE; LITHIUM; PAROXETINE; PLACEBO;

ANXIETY; ARTICLE; BEHAVIOR CHANGE; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; COMPARATIVE EFFECTIVENESS; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERSOMNIA; INCREASED APPETITE; MAJOR CLINICAL STUDY; MOOD; PILL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUICIDE; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

AFFECT; ANTIDEPRESSIVE AGENTS; ANXIETY; COGNITION; COGNITIVE THERAPY; DEPRESSION; HUMANS; PAROXETINE; SUICIDAL IDEATION; SYMPTOM ASSESSMENT;

EID: 84877132692     PISSN: 00057967     EISSN: 1873622X     Source Type: Journal    
DOI: 10.1016/j.brat.2013.03.010     Document Type: Article

References (42)

1. Aarons S.F., Frances A.J., Mann J.J. Atypical depression: a review of diagnosis and treatment. Hospital and Community Psychiatry 1985, 36:275-282.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Press, Washington, DC. Text Revision, 4th ed.
3. American Psychiatric Association Treatment of patients with major depressive disorder 2010, American Psychiatric Association, Washington, DC. 3rd. ed.
4. Angst J., Gamma A., Benazzi F., Ajdacic V., Rössler W. Melancholia and atypical depression in the Zurich study: epidemiology, clinical characteristics, course, comorbidity and personality. Acta Psychiatrica Scandinavica Supplementum 2007, 72-84.
5. Bagby R.M., Ryder A.G., Schuller D.R., Marshall M.B. The Hamilton depression rating scale: has the gold standard become a lead weight?. American Journal of Psychiatry 2004, 161:2163-2177.
6. Barber J.P., DeRubeis R.J. On second thought: where the action is in cognitive therapy for depression. Cognitive Therapy and Research 1989, 13:441-457.
7. Beck A.T., Rush A.J., Shaw B.F., Emery G. Cognitive therapy of depression 1979, The Guilford Press, New York.
8. Bhar S.S., Gelfand L.A., Schmid S.P., Gallop R., DeRubeis R.J., Hollon S.D., et al. Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy. Journal of Affective Disorders 2008, 110:161-166.
9. Caley C.F., Weber S.S. Paroxetine: a selective serotonin reuptake inhibiting antidepressant. The Annals of Pharmacotherapy 1993, 27:1212-1221.
10. Cole J.C., Motivala S.J., Dang J., Lucko A., Lang N., Levin M.J., et al. Structural validation of the Hamilton Depression Rating Scale. Journal of Psychopathology and Behavioral Assessment 2004, 26:241-254.
11. DeRubeis R.J., Evans M.D., Hollon S.D., Garvey M.J., Grove W.M., Tuason V.B. How does cognitive therapy work? Cognitive change and symptom change in cognitive therapy and pharmacotherapy for depression. Journal of Consulting and Clinical Psychology 1990, 58:862-869.
12. DeRubeis R.J., Hollon S.D., Amsterdam J.D., Shelton R.C., Young P.R., Salomon R.M., et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Archives of General Psychiatry 2005, 62:409-416.
13. DiMascio A., Weissman M.M., Prusoff B.A., Neu C., Zwilling M., Klerman G.L. Differential symptom reduction by drugs and psychotherapy in acute depression. Archives of General Psychiatry 1979, 36:1450-1456.
14. Domschke K., Deckert J., Arolt V., Baune B. Anxious versus non-anxious depression: difference in treatment outcome. Journal of Psychopharmacology 2010, 24:621-622.
15. Farabaugh A.H., Bitran S., Witte J., Alpert J., Chuzi S., Clain A.J., et al. Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. International Clinical Psychopharmacology 2010, 25:214-217.
16. Fava M., Rush A.J., Alpert J.E., Balasubramani G.K., Wisniewski S.R., Carmin C.N., et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. The American Journal of Psychiatry 2008, 165:342-351.
17. Fink M., Bolwig T.G., Parker G., Shorter E. Melancholia: restoration in psychiatric classification recommended. Acta Psychiatrica Scandinavica 2007, 115:89-92.
18. First M., Spitzer R., Gibbon M., Williams J. Structured Clinical Interview for DSM-IV-TR-Axis I Disorders 2001, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/PSY SCREEN), Biometrics Research, New York State Psychiatric Institute, New York, NY.
19. Garratt G., Ingram R.E., Rand K.L., Sawalani G. Cognitive processes in cognitive therapy: evaluation of the mechanisms of change in the treatment of depression. Clinical Psychology: Science and Practice 2007, 14:224-239.
20. Gorsuch R.L. Factor analysis 1983, Erlbaum, Hillsdale, NJ. 2nd ed.
21. Hamilton M.A. Arating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 1960, 23:56-62.
22. Harmer C.J., Goodwin G.M., Cowen P.J. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. The British Journal of Psychiatry: The Journal of Mental Science 2009, 195:102-108.
23. Hedeker D., Gibbons R.D. Longitudinal data analysis 2006, John Wiley & Sons, Inc, Hoboken, NJ.
24. Hollon S.D., DeRubeis R.J., Evans M. Causal mediation of change in treatment for depression: discriminating between nonspecificity and noncausality. Psychological Bulletin 1987, 102:139-149.
25. Hollon S.D., DeRubeis R.J., Shelton R.C., Amsterdam J.D., Salomon R.M., O'Reardon J.P., et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Archives of General Psychiatry 2005, 62:417-422.
26. Hollon S.D., Jarrett R.B., Nierenberg A.A., Thase M.E., Trivedi M., Rush A.J. Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment?. Journal of Clinical Psychiatry 2005, 66:455-468.
27. Hollon S.D., Stewart M.O., Strunk D. Enduring effects for cognitive behavior therapy in the treatment of depression and anxiety. Annual Review of Psychology 2006, 57:285-315.
28. Imber S.D., Pilkonis P.A., Sotsky S.M., Elkin I., Watkins J.T., Collins J.F., et al. Mode-specific effects among three treatments for depression. Journal of Consulting and Clinical Psychology 1990, 58:352-359.
29. Jacobson N.S., Hollon S.D. Cognitive-behavior therapy versus pharmacotherapy: now that the jury's returned its verdict, it's time to present the rest of the evidence. Journal of Consulting and Clinical Psychology 1996, 64:74-80.
30. Mallinckrodt C.H., Prakash A., Houston J.P., Swindle R., Detke M.J., Fava M. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology 2007, 56:73-85.
31. Meterissian G.B., Bradwejn J. Comparative studies on the efficacy of psychotherapy, pharmacotherapy, and their combination in depression: was adequate pharmacotherapy provided?. Journal of Clincal Psychopharmacology 1989, 9:334-339.
32. Raudenbush S.W., Bryk A.S. Hierarchical linear models: Applications and data analysis methods 2002, Sage Publication, London. 2nd ed.
33. Rector N.A., Bagby R.M., Segal Z.V., Joffe R.T., Levitt A. Self-criticism and dependency in depressed patients treated with cognitive therapy or pharmacotherapy. Cognitive Therapy and Research 2000, 24:571-584.
34. Reimherr F.W., Amsterdam J.D., Quitkin F.M., Rosenbaum J.F., Fava M., Zajecka J., et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. American Journal of Psychiatry 1998, 155:1247-1253.
35. Rush A.J., Kovacs M., Beck A.T., Weissenburger J., Hollon S.D. Differential effects of cognitive therapy and pharmacotherapy on depressive symptoms. Journal of Affective Disorders 1981, 3:221-229.
36. Serretti A., Mandelli L., Lattuada E., Cusin C., Smeraldi E. Clinical and demographic features of mood disorder subtypes. Psychiatry Research 2002, 112:195-210.
37. Shafer A.B. Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. Journal of Clinical Psychology 2005, 62:123-146.
38. Spitzer R., Williams J., Gibbon M., First M. Structured Clinical Interview for DSM-II-R personality disorders (SCID-II, Version 1.0) 1990, American Psychiatric Press, Washington, DC.
39. Stewart J.G., Harkness K.L. Symptom specificity in the acute treatment of major depressive disorder: a re-analysis of the treatment of depression collaborative research program. Journal of Affective Disorders 2012, 137:87-97.
40. Taylor D.J., Walters H.M., Vittengl J.R., Krebaum S., Jarrett R.B. Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence?. Journal of Affective Disorders 2010, 123:181-187.
41. Thase M., Frank E., Mallinger A., Hamer T., Kupfer D. Treatment of imipramine-resistant recurrent depression III: efficacy of monoamine oxidase inhibitors. Journal of Clinical Psychiatry 1992, 53:5-11.
42. Vaishnavi S., Gadde K., Alamy S., Zhang W., Connor K., Davidson J.R.T. Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. Journal of Clinical Psychopharmacology 2006, 26:373-378.